According to FDA drug labeling, concomitant use of the fixed-dose combination abacavir, lamivudine, and zidovudine with doxorubicin should be avoided. The source material indicates a documented in vitro antagonistic relationship between these medications. This means that evidence from laboratory studies has shown the two drugs work against each other's intended effects, and the interaction is classified as contraindicated—a level of severity that recommends avoiding the combination when possible.
The documented interaction record comes from FDA drug labeling for the combination product abacavir, lamivudine, and zidovudine (also known by brand names including Trizivir). The key facts are:
This is a controlled piece of clinical information, meaning it derives from formal FDA regulatory documentation rather than theoretical concern or expert opinion. When FDA labeling uses the term "should be avoided," it signals a serious compatibility problem that warrants discussion with both a physician and pharmacist before any decision is made to use these drugs in combination.
To grasp what "antagonistic relationship" means in this context, it helps to separate what is documented from general pharmacology background.
What the source record documents: Laboratory studies (in vitro tests conducted in cells or solutions outside the body) have shown that zidovudine and doxorubicin interfere with each other's function. The record does not specify the exact cellular or molecular mechanism; it simply states that antagonism has been demonstrated. This is important: the fact of the antagonism is established, but the underlying "why" is not spelled out in the source material.
General background (not proof of this specific interaction): Both zidovudine and doxorubicin are drugs that affect how cells replicate and die. Zidovudine is a nucleoside reverse transcriptase inhibitor—it blocks an HIV enzyme and interrupts viral replication by interfering with the HIV life cycle. Doxorubicin is a chemotherapy agent that damages cell DNA and causes cancer cells to die. Because both drugs touch cell division and DNA processes, it might seem plausible that they could interfere with each other. However, this plausibility alone does not establish that the interaction occurs. The documented in vitro antagonism is what matters here, and that finding is controlling for this article.
The term "in vitro antagonism" means that when researchers placed these drugs together in laboratory conditions—typically in cells grown in a dish or in a test-tube system—the presence of one drug reduced or blocked the intended activity of the other. This is different from a simple additive effect (where both drugs work but independently) or a synergistic effect (where both drugs work together and enhance each other). Antagonism is opposition: the drugs work against each other.
Because this effect has been documented in laboratory conditions, the FDA labeling advises that the drugs should not be used together unless there is a compelling clinical reason and close medical supervision. This is a precaution based on evidence, not speculation.
This interaction is relevant to any patient who is currently taking or considering the fixed-dose combination of abacavir, lamivudine, and zidovudine and who also needs doxorubicin therapy, or vice versa.
Patients with HIV who develop a cancer requiring doxorubicin treatment represent a key clinical scenario. Similarly, patients with cancer who have HIV and are on this antiretroviral regimen would need careful medication review. However, this is not a narrow concern: the contraindication applies across all patient populations in which both drugs are being considered, regardless of age, sex, comorbidity, or other factors.
It is also worth noting that abacavir, lamivudine, and zidovudine is a fixed-dose combination tablet, meaning all three antiretroviral drugs are combined in a single pill. If an interaction exists with any component of that combination, it affects the whole regimen. The interaction record specifically identifies zidovudine (also called AZT) as the component with the documented antagonism, but the source material groups all three together because they are dispensed as one product.
Scenario 1: Imagine a patient with HIV who has been stable on a regimen including abacavir, lamivudine, and zidovudine for several years. The patient is then diagnosed with breast cancer and an oncologist recommends doxorubicin-based chemotherapy. Before starting chemotherapy, the medical team would need to review this documented antagonistic interaction. The goal would be to decide whether the antiretroviral regimen can be changed to a different HIV drug combination that does not interact with doxorubicin, allowing the cancer treatment to proceed safely. This is not a simple decision—it would require weighing HIV viral load control against cancer treatment efficacy—but the in vitro antagonism documented in FDA labeling would be a central factor in the conversation.
Scenario 2: A patient receiving doxorubicin for lymphoma is also living with HIV. At the time of cancer diagnosis, the patient's HIV regimen is reviewed. If abacavir, lamivudine, and zidovudine is the current treatment, the HIV specialist and oncologist would likely coordinate to explore alternative antiretroviral options. The documented antagonistic relationship means that continuing this particular combination alongside doxorubicin would not be optimal, even though HIV treatment cannot simply be stopped. Both teams would work to find a solution that controls HIV while permitting effective chemotherapy.
Both scenarios underscore a key point: this is not an interaction that forces an absolute prohibition in every single case, but rather one that triggers a serious clinical conversation and typically leads to medication adjustment or close monitoring if the combination cannot be avoided.
If you are taking abacavir, lamivudine, and zidovudine and your doctor recommends doxorubicin, or if you are on doxorubicin and taking this antiretroviral combination, here are evidence-based questions and considerations to raise with your care team:
To check whether abacavir, lamivudine, and zidovudine, doxorubicin, or any of your other medications have documented interactions, visit checkdruginteractions.com and enter your medication list. A comprehensive drug interaction check can identify other pairs you may not have considered and help you and your pharmacist ensure your regimen is as safe as possible. Always confirm any medication decision—including whether to continue, change, or stop a drug—with your pharmacist or physician. This article explains what the source material documents, but your healthcare provider must apply that information to your individual medical situation.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Documented contraindicated interaction: concomitant use risks antagonism and bone marrow suppression. Source-based guidance for patients ...
FDA-sourced: concomitant use of 5-HT1b/1d agonists (triptans) and almotriptan within 24 hours is contraindicated. Learn what this means.
Learn why combining different triptans or using another triptan within 24 hours of sumatriptan is contraindicated and carries serious vas...